Concentric Medical and Gaoke Technology have submitted their IPO applications to the Shanghai Stock Exchange and have received inquiries.
Tongxin Healthcare and Gaokai Technology's IPO on the Shanghai Stock Exchange has received inquiries.
On January 15th, Suzhou Tongxin Medical Technology Co., Ltd. (referred to as Tongxin Medical) and Jiangsu Gaokai Precision Fluid Technology Co., Ltd. (referred to as Gaokai Technology) are in the "inquiry" stage of IPO review, with CITIC SEC and Guotai Haitong as the sponsoring institutions.
According to the prospectus, Tongxin Medical is a global Innovative Medical Management device company that promotes the advancement and market development of late-stage heart failure treatment through breakthrough new technologies and solutions. In terms of product internationalization, in the Chinese market, the company's first implantable full magnetic levitation left ventricular assist system CH-VAD has been approved for listing by the National Medical Products Administration, becoming the first fully magnetically levitated implantable artificial heart to be approved for listing in China. Its iterative version, CH-VAD Plus, is currently in the registration stage and is expected to be approved for listing in China in early 2026; in the U.S. market, the company's new generation implantable full magnetic levitation left ventricular assist system BrioVAD has been approved by the U.S. FDA for clinical trials, becoming the first actively implantable medical device from China to be approved for clinical trials by the FDA.
Gaokai Technology specializes in the research, development, production, and sales of key control components and related equipment in the field of precision fluid control. Through continuous efforts, the company's product layout continues to improve, with its products currently focusing on flow control series, dispensing packaging series, and precision dispensing series as the core, and extending to more types of precision fluid control components and related equipment, such as semiconductor vacuum system components, widely used in smart manufacturing fields such as semiconductors, consumer electronics, automotive electronics, and new energy.
Related Articles

ZHONGZHIPHARM(03737) issues a profit warning, expecting a decrease in annual net profit of no less than 70%.

SUNHO BIO-B(02898): Jiang Xiaoling appointed as Chief Executive Officer and Chief Scientific Officer

RIMAG GROUP (02522) has issued 6.13 million H shares of bonus shares.
ZHONGZHIPHARM(03737) issues a profit warning, expecting a decrease in annual net profit of no less than 70%.

SUNHO BIO-B(02898): Jiang Xiaoling appointed as Chief Executive Officer and Chief Scientific Officer

RIMAG GROUP (02522) has issued 6.13 million H shares of bonus shares.

RECOMMEND

Paul Chan Says Hong Kong Has Licensed 11 Virtual Asset Exchanges, Stablecoin Licenses Expected Later This Year
22/01/2026

Ministry Of Finance And Other Departments Introduce Comprehensive Fiscal And Financial Policies To Boost Domestic Demand
22/01/2026

Capital Migration: Five Years On, An In‑Depth Analysis Of China’s 11 High‑Growth Venture Capital Tracks In 2025
22/01/2026


